Evaluation of Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis (SCLEROPIDEVOL Study)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and represents the main cause of mortality. Disease course in SSc-ILD is highly variable: patients can experience stable disease, slow or fast progression. Prevention of ILD progression now represents a key objective of SSc-ILD management. The understanding of the course and patterns of SSc-ILD progression is necessary, as reliable prediction tools that allow the stratification of the risk of progression. We aimed to identify the longitudinal trajectories of ILD in SSc patients using latent class mixed models and to examine their associations with SSc characteristics.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with systemic sclerosis according to 2013 ACR/EULAR criteria

• Patients with interstitial lung disease on HRCT chest

• Patients with PFT at ILD diagnosis and at least 1 PFT evaluation during follow-up

Locations
Other Locations
France
CHU Nancy
RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
Paul DECKER, MD
p.decker@chru-nancy.fr
+33383157240
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2025-09-01
Participants
Target number of participants: 600
Treatments
SSc-ILD patients
Sponsors
Leads: Central Hospital, Nancy, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials